Answers are grounded in this paper and cite their sources.
Canine mast cell tumours (MCTs) show variable biological behaviour, ranging from localized tumours to aggressive disease with regional lymph node involvement. Understanding cellular features associated with this variability may help characterize their biological behaviour. Ezrin, a member of the ERM protein family involved in cell motility, has been associated with tumour progression in several neoplasms. However, its role in canine MCT remains unclear. This study aimed to evaluate ezrin immunoreactivity and its association with regional lymph node histological status in a retrospective series of 27 canine cutaneous and subcutaneous MCTs. Cytoplasmic and membranous immunolabelling were scored by intensity and percentage of positive neoplastic cells. Cytoplasmic positivity exceeded 50% in 26/27 tumours (96.3%) and membranous positivity exceeded 50% in 19/27 (70.4%). Histological lymph node categories (HN0-HN3) were documented for 26 tumours. The ordinal percentage score for membranous immunolabel correlated positively with HN category (Spearman's ρ = 0.418, two-sided p = 0.034; n = 26), whereas the combined membranous score did not (ρ = 0.259, p = 0.202). The diffuse immunolabelling pattern also showed no statistically significant correlation with HN category (ρ = 0.165, p = 0.430; n = 25). These findings suggest an association between the proportion of MCT cells showing membranous ezrin immunoreactivity and regional lymph node histological status. Further studies are required in order to enlighten ezrin's role in MCT disease evolution.
No takes yet. Share an insight, caveat, or question.
Santos et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: